Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.

Press releases

20. October 2022

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharmato Develop First-in-Class Celiac Disease Therapy

Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China Agreement Adds Third Investigational Therapy to Takeda’s Pipeline for the Potential Treatment of Celiac Disease Osaka, Japan, and Freiburg and Darmstadt, Germany, October 20, 2022 – Takeda, Zedira and Dr. Falk Pharma GmbH today announced a collaboration and licensing agreement to develop ZED1227/T

Info & Contact

Ralf Pasternack


Roesslerstraße 83
64293 Darmstadt

In portfolio

03. Sep 2007

HTGF Manager

Marco Winzer, Partner